Nipro newsletter April 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

DDL 2026
Merxin March 2026
Terumo 05/01
Nipro April 2026
SAE Media – Pre-filled syringes West Coast 19/11/25

Optimising the HPAPI Value Chain to Achieve Maximised Product Value

In the quest to find new and more effective treatments against severe diseases, researchers are increasingly moving towards active pharmaceutical ingredients (APIs) with increased potency and more targeted delivery mechanisms. These powerful compounds may help treat life-threatening and so-far incurable diseases, including cancer, diabetes, Parkinson’s disease, and others. Maurits Janssen at Lonza Pharma & Biotech showcases why sustainable manufacturing of highly potent APIs (HPAPIs) requires specific precautions to operator health and safety on the one side and to product quality on the other.

 

SMI London
Biopharma group march 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025